AAT-008 / AskAt, Ikena Oncology - LARVOL DELTA

Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. (PubMed, Transl Cancer Res) - "In the second FCM series, the mean Treg proportion and Teff/Treg ratio in the 0 mg + RT and 30 mg + RT groups were 4.0% and 1.5%, respectively (P=0.04) and 10 and 22, respectively (P=0.04). AAT-008 potentially enhances the radiosensitivity of colon cancer cells, apparently by stimulating the immune system against the cancer cells."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD69

[VIRTUAL] Biological Effects of Prostagrandin E2-EP4 Antagonist (AAT-008): Enhancement of Immunoresponse to Radiotherapy and a Potential As a Radiosensitizer (ASTRO 2021) - "AAT-008 had a potential of enhancing radiosensitivity in the treatment of colon cancer cells. It was assumed that the optimal dose of AAT-008 with RT was 10 mg/kg/day. It was suggested that AAT-008 stimulated the immune system against the cancer cells."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Transplantation • CD69 • CD8 • FOXP3 • PTPRC

Biological Effects of Prostagrandin E2-EP4 Antagonist (AAT-008): Enhancement of Immunoresponse to Radiotherapy and a Potential as a Radiosensitizer. (PubMed, Int J Radiat Oncol Biol Phys) - "AAT-008 had a potential of enhancing radiosensitivity in the treatment of colon cancer cells. It was assumed that the optimal dose of AAT-008 with RT was 10 mg/kg/day. It was suggested that AAT-008 stimulated the immune system against the cancer cells."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Transplantation • CD69 • CD8 • FOXP3 • PTPRC

"#NationalInstituteOfIndustrialProperty (Instituto Nacional da Propriedade Industrial: INPI) Approves Substance Patent for #AskAt’s #EP4Antagonist (#AAT008) In Brazil https://t.co/sQbrFONdjq" (@1stOncology)